Episodic Migraine

Lower Dose DFN-11 for Episodic Migraine Associated With Fewer Side Effects

Lower Dose DFN-11 for Episodic Migraine Associated With Fewer Side Effects

By

DFN-11, a 3 mg subcutaneous sumatriptan autoinjector, may provide an alternative to SC sumatriptan 6 mg for individuals with episodic migraine.

New Device Available for Patients With Episodic Cluster Headache, Migraine

New Device Available for Patients With Episodic Cluster Headache, Migraine

By

GammaCore Sapphire, a new non-invasive hand-held device for migraine and episodic cluster headache treatment, has been made available by electroCore.

Galcanezumab Beats Placebo for Episodic Migraine

Galcanezumab Beats Placebo for Episodic Migraine

For patients with episodic migraine, galcanezumab is better than placebo for reducing migraine headache days.

Fremanezumab effective in preventing episodic migraine

Fremanezumab slightly decreased the amount of headache free days in those with episodic migraines compared to placebo.

Pain, Psychiatric Comorbidities More Common in Chronic vs Episodic Migraine

Pain, Psychiatric Comorbidities More Common in Chronic vs Episodic Migraine

By

Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.

Erenumab for Episodic Migraine: A Closer Look at the Data

Erenumab for Episodic Migraine: A Closer Look at the Data

By

For individuals with migraine frequency of 4 to 14 episodes per month, prophylactic medications and analgesics are required.

Erenumab, Fremanezumab Reduce Migraine Frequency, Burden

Erenumab, Fremanezumab Reduce Migraine Frequency, Burden

By

Both erenumab and fremanezumab are currently under review by the FDA for the treatment of migraine.

Episodic Migraine Increases Risk for CVD, Subsequent Contraindications to Therapy

Episodic Migraine Increases Risk for CVD, Subsequent Contraindications to Therapy

By

Clinicians need to consider treatments for episodic migraine that may be contraindicated if a patient also has cardiovascular disease.

Using Perceived Stress to Predict Episodic Migraine Attacks

Using Perceived Stress to Predict Episodic Migraine Attacks

By

Future predictive models may need to include other migraine risk factors to enhance predictive accuracy.

Monthly Migraine Days Reduced With CGRP Antagonist Erenumab

Monthly Migraine Days Reduced With CGRP Antagonist Erenumab

By

Treatment with the monoclonal antibody erenumab reduced the number of monthly migraine days experienced in patients with episodic migraine.

Predictors of Poor Treatment Response in Episodic Migraine

Predictors of Poor Treatment Response in Episodic Migraine

By

Over 50% of participants reported having an inadequate response to treatment.

Monoclonal Antibody Efficacious for Treatment of Migraines

Monoclonal Antibody Efficacious for Treatment of Migraines

By

Phase 2 results show anti-CGRP receptor monoclonal antibody effective for the prevention of episodic migraine.

Depression, Pain Sensitivity May Affect Migraine Treatment Response

Depression, Pain Sensitivity May Affect Migraine Treatment Response

By

Treatment that provides rapid, consistent migraine relief may help mediate factors that promote inadequate treatment response.

Simvastatin, Vitamin D3 Combo Effective in Episodic Migraine

Simvastatin, Vitamin D3 Combo Effective in Episodic Migraine

Adults taking the drug combo experienced a decreased amount of migraine days compared to placebo.

Lipid Panel May Identify Episodic Migraine in Migraineurs

Lipid Panel May Identify Episodic Migraine in Migraineurs

By

A simple lipid panel may distinguish those with episodic migraine.

Sign Up for Free e-newsletters



CME Focus